Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026)

Neumora Therapeutics' (NMRA) quarterly Debt Ratio came in at 0.34 in Q1 2026, up 20.58% quarter-over-quarter from 0.29 in Q4 2025.

Neumora Therapeutics (NMRA) Debt Ratio (2025 - 2026) Analysis & Trends

Neumora Therapeutics' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.34 for Q1 2026.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.34 in Q1 2026; TTM through Mar 2026 was 0.34, a N/A change from a year earlier, with the FY2025 full-year figure at 0.29, changed N/A from the prior year.
Debt Ratio climbed to 0.34 in Q1 2026 per NMRA's latest filing, from 0.29 in the prior quarter.
Across five years, Debt Ratio topped out at 0.34 in Q1 2026 and bottomed at 0.09 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Neumora Therapeutics	280.60 Mn	280.60 Mn	-	0.34

Download Data